Allogene Therapeutics Days Of Inventory Outstanding Over Time

ALLO Stock  USD 2.02  0.12  5.61%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Allogene Therapeutics Performance and Allogene Therapeutics Correlation.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
  
As of the 13th of December 2024, Days Of Inventory Outstanding is likely to drop to -1,288.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.55)
Quarterly Revenue Growth
(0.27)
Return On Assets
(0.26)
Return On Equity
(0.54)
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Days Of Inventory Outstanding Analysis

Compare Allogene Therapeutics and related stocks such as G1 Therapeutics, Heron Therapeuti, and Annexon Days Of Inventory Outstanding Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
HRTX60.833355.7 K55.7 K55.7 K55.7 K55.7 K55.7 K804518148423384363236224
ANNX(1.6417)(1.6417)(1.6417)(1.6417)(1.6417)(1.6417)(1.6417)(1.6417)(1.6417)(1.6417)(1.6417)(1.6417)(1.6417)(1.48)(1.55)
SGMO(144)(144)(144)(377)(301)(1.6693)(1.246)(6.9526)(1.1916)(56.3151)(102)(3.4 K)0.00.00.0
BEAM(13.5 K)(13.5 K)(13.5 K)(13.5 K)(13.5 K)(13.5 K)(13.5 K)(13.5 K)(13.5 K)(13.5 K)(13.5 K)(13.5 K)(13.5 K)(12.1 K)(12.7 K)
SANA0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
CRBU49.140349.140349.140349.140349.140349.140349.140349.140349.140349.140325.7965(11.5 K)(6.3 K)(7.2 K)(7.6 K)
EDIT15.106715.106715.106715.106715.106715.106710.64668.181411.7487(253)(253)(8.7 K)(5.4 K)(6.2 K)(5.9 K)
RLAY(24.5 K)(24.5 K)(24.5 K)(24.5 K)(24.5 K)(24.5 K)(24.5 K)(24.5 K)(24.5 K)(24.5 K)(24.5 K)(63.5 K)1.1 K963K
IPSC3.4 K3.4 K3.4 K3.4 K3.4 K3.4 K3.4 K3.4 K3.4 K3.4 K391(19.9149)(19.9149)(22.9)(21.76)
BPMC(243)(243)(243)(243)(243)(243)(243)0.00.07.4 K7.4 K444609605575
NTLA0.00.00.00.00.00.00.00.00.00.0(46.4622)(17.9 K)(3.3 K)(3.8 K)(4 K)
VERV1.0E-41.0E-41.0E-41.0E-41.0E-41.0E-41.0E-41.0E-41.0E-41.0E-41.0E-41.0E-41.0E-40.00.0
ITOS(222)(222)(222)(222)(222)(222)(222)(222)(222)(222)(222)(222)(222)(200)(210)

Allogene Therapeutics and related stocks such as G1 Therapeutics, Heron Therapeuti, and Annexon Days Of Inventory Outstanding description

My Equities

My Current Equities and Potential Positions

Allogene Therapeutics
ALLO
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationCalifornia; U.S.A
ExchangeNASDAQ Exchange
USD 2.02
When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:
Check out Allogene Therapeutics Performance and Allogene Therapeutics Correlation.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Allogene Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Allogene Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Allogene Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...